PACCAR
PCAR
$102.42
-1.26%
Paccar Inc is a leading manufacturer of medium- and heavy-duty commercial trucks sold under the premium Kenworth and Peterbilt nameplates in the Americas and Australia, and the DAF brand in Europe and South America, supported by a captive finance arm and a growing aftermarket parts business. The company is a premium-tier incumbent rather than a disruptor, commanding roughly 30% of the North American Class 8 market and about 15% of the European heavy-duty market, with its 2,200-dealer network and vertically integrated powertrain components (engines, axles, transmissions) forming a durable competitive moat. The current investor debate centers on a cyclical freight downturn that has compressed truck deliveries and margins, evidenced by revenue growth of just 0.48% year over year in the most recent quarter and a 19% three-month share price decline, even as bulls point to AI-driven data-center infrastructure spending and urbanization trends lifting industrial equipment demand. Sentiment is further complicated by Paccar's premium valuation relative to its own history despite decelerating fundamentals, and by a notable RBC Capital upgrade to Outperform in September 2026 that suggests some analysts see the cycle bottoming.…
PCAR
PACCAR
$102.42
Related headlines
Investment Opinion: Should I buy PCAR Today?
Rating: Hold. The core thesis is that Paccar is a high-quality industrial franchise trading at a premium trailing multiple (24.23x) during a cyclical downturn, with a forward PE of 14.94x that prices in a 62% earnings recovery. The analyst consensus rating of 'buy' (mean 2.21) and average target price of $133.38 imply 24.7% upside, but the wide target range ($107 to $162) and split institutional ratings reflect genuine uncertainty about the timing of the cycle inflection. We recommend a Hold until there is clearer evidence of a revenue and margin recovery.
Supporting evidence for the Hold includes: (1) revenue growth has decelerated to 0.48% year over year in Q2 2026, with the core truck business in a cyclical trough; (2) gross margin has compressed from 18.60% in Q4 2024 to 16.07% in Q2 2026, and EBITDA margin from 15.17% to 11.65%; (3) the trailing PE of 24.23x is near the top of its historical range, while the forward PE of 14.94x offers a more reasonable entry if earnings recover; (4) the dividend yield of 3.94% provides income support, but the payout ratio of 95.4% limits growth; and (5) the balance sheet is strong with a current ratio of 3.08 and $5.57 billion in cash. The implied upside to the analyst average target is 24.7%, but the low target of $107.00 suggests limited downside protection if the cycle disappoints.
The biggest risks that could invalidate the thesis are: (1) a prolonged freight recession leading to further revenue and margin compression, potentially pushing the stock toward the 52-week low of $93.86; (2) valuation compression if the forward EPS estimate of $9.29 proves too optimistic, with the trailing PE already near historical highs; and (3) competitive and regulatory pressures from zero-emission powertrains and stricter emissions standards. The rating would upgrade to Buy if revenue growth accelerates above 5% and gross margins stabilize above 17%, or if the stock price falls below $95 (near the 52-week low) while the forward PE remains below 12x. It would downgrade to Sell if revenue declines year over year and gross margins fall below 15%. Relative to its history and peers, the stock appears fairly valued on a forward basis but overvalued on trailing metrics, leaving limited margin of safety.
Sign up to view all
PCAR 12-Month Price Forecast
We maintain a neutral stance with medium confidence, balancing the potential for a cyclical recovery against near-term fundamental deterioration. The forward PE of 14.94x suggests the market is already pricing in a significant earnings rebound, while the trailing PE of 24.23x leaves little room for disappointment. The analyst consensus of 'buy' with a $133.38 target is constructive, but the wide target range ($107-$162) and split institutional ratings reflect genuine uncertainty. We would upgrade to bullish if revenue growth accelerates above 5% and gross margins stabilize above 17%, or if the stock falls below $95 with a forward PE below 12x. We would downgrade to bearish if revenue declines year over year and gross margins fall below 15%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on PACCAR's 12-month outlook, with a consensus price target around $132.69 and implied upside of +29.6% versus the current price.
Average Target
$132.69
0 analysts
Implied Upside
+29.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$107 - $162
Analyst target range
Coverage is robust with 16 analysts, and the consensus recommendation of "buy" (mean rating 2.21 on a scale where lower is more bullish) leans constructive despite the stock's sharp decline. The average target price of $133.38 implies roughly +24.7% upside from the current $106.96, a meaningful gap that suggests the sell-side views the recent weakness as an overshoot relative to fundamental value. The consensus is moderately bullish rather than euphoric, consistent with a cyclical name where analysts see recovery but disagree on timing. The target range is wide, from a low of $107.00 — essentially at the current price, implying zero upside — to a high of $162.00, a +51.5% premium that would require multiple expansion and a confirmed freight-cycle upturn. The low target effectively prices in continued margin compression and no earnings recovery, while the high target assumes the forward EPS estimate of $9.29 is achieved and the market re-rates the stock toward its historical peak multiples. Institutional actions show a constructive tilt: RBC Capital upgraded to Outperform from Sector Perform on September 10, 2026, and JP Morgan and Evercore ISI maintain Overweight/Outperform ratings, though Morgan Stanley, Wells Fargo, Citigroup, and Truist remain at Equal Weight, Neutral, or Hold — a split that reflects genuine debate about the cycle's inflection point and explains the wide $55 target spread.
Bulls vs Bears: PCAR Investment Factors
The bear case currently has stronger evidence: revenue growth has stalled at 0.48%, margins are compressing, and the stock is in a clear downtrend with a -19% three-month decline. However, the bull case rests on a powerful forward-looking argument: the forward PE of 14.94x implies a 62% earnings recovery, and the analyst consensus target of $133.38 suggests 24.7% upside. The single most important tension is whether the freight cycle is bottoming—if it is, the forward earnings recovery will materialize and the stock is cheap; if it is not, the trailing PE of 24.23x is vulnerable to further compression. The RBC upgrade to Outperform in September 2026 and the wide analyst target range ($107 to $162) reflect genuine debate about the timing of the inflection.
Bullish
- Analyst consensus sees 24.7% upside: The 16-analyst consensus rating is 'buy' (mean 2.21) with an average target of $133.38, implying +24.7% upside from $106.96. The low target of $107.00 is essentially at the current price, suggesting the sell-side views the recent decline as an overshoot.
- Forward PE of 14.94x prices recovery: Trailing PE of 24.23x versus forward PE of 14.94x implies the market expects EPS to grow ~62% to the consensus $9.29. If achieved, the stock would trade at a reasonable multiple for an industrial cyclical, providing a clear path to valuation support.
- Fortress balance sheet and cash generation: Current ratio of 3.08, debt-to-equity of 0.81, and $5.57 billion in cash provide ample liquidity. Trailing free cash flow of $3.13 billion and ROE of 12.33% demonstrate the business still generates substantial cash even in a downturn.
- Dividend yield of 3.94% offers income support: The stock pays a 3.94% dividend yield, well above the market average, providing a meaningful income cushion for patient holders. However, the payout ratio of 95.4% leaves little room for growth without earnings recovery.
Bearish
- Revenue growth has stalled at 0.48%: Q2 2026 revenue of $7.55 billion grew only 0.48% year over year, and the multi-quarter trend is deteriorating, with revenue falling from $7.91 billion in Q4 2024 to $6.67 billion in Q3 2025. The core truck business (74% of sales) is in a cyclical trough.
- Margins are compressing sharply: Gross margin fell to 16.07% in Q2 2026 from 16.99% a year earlier and 18.60% in Q4 2024. EBITDA margin of 11.65% versus 15.17% a year ago confirms operating leverage working in reverse.
- Trailing PE near historical high: The trailing PE of 24.23x sits near the top of its historical range (9x to 25.8x) even as earnings decline, flagging that the market is pricing in an optimistic cyclical recovery. The PEG ratio of -0.56 is not meaningful given negative growth.
- Technical downtrend with -19% 3-month decline: The stock is down 19.12% over three months and 4.58% over one month, with relative strength versus SPY of -21.97% over three months. It sits just 13.9% above the 52-week low of $93.86, and a breakdown below that level would signal further de-rating.
PCAR Technical Analysis
Paccar is in a clear intermediate downtrend despite a still-positive one-year return of +7.63%, with the stock having fallen from a 52-week high of $139.24 to $106.96, placing it at roughly 28.8% of its 52-week range (range width of $45.38). That positioning near the lower quartile signals the stock is closer to a value-opportunity zone than a momentum extension, but the persistent series of lower highs since the July peak argues against calling a bottom prematurely. The one-year gain masks severe deterioration in the interim, and the current price sits just 13.9% above the 52-week low of $93.86, a level that has not been tested since the spring. Recent momentum is decisively negative and accelerating: the stock is down 4.58% over one month and 19.12% over three months, with the three-month decline far outpacing the one-year gain and producing a relative strength versus SPY of -21.97% over three months and -22.23% over six months. This divergence between a positive 12-month return and a sharply negative 3-month trend is characteristic of a trend reversal rather than a temporary pullback, and the most recent session's -2.40% drop to $106.96 on volume of roughly 2.05 million shares confirms sellers remain in control. Key support sits at the 52-week low of $93.86, and a breakdown below that level would signal the cyclical de-rating has further to run; resistance is anchored at the $139.24 high, with intermediate supply likely near the $120-$125 area where the stock repeatedly stalled in August and September. With a beta of 0.988, Paccar's volatility is essentially in line with the broader market, so the -22.68% maximum drawdown reflects stock-specific cyclical pressure rather than elevated systematic risk, though position sizing should still account for the 19% three-month slide and the possibility of further downside toward the 52-week low.
Beta
—
—
Max Drawdown
-25.9%
Largest decline past year
52-Week Range
$94-$139
Price range past year
Annual Return
+3.3%
Cumulative gain past year
| Period | PCAR Return | S&P 500 |
|---|---|---|
| 1m | -8.3% | +0.9% |
| 3m | -23.4% | +4.1% |
| 6m | -11.8% | +7.2% |
| 1y | +3.3% | +12.4% |
| ytd | -8.2% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PCAR Fundamental Analysis
Revenue growth has decelerated sharply to near-stagnation: Q2 2026 revenue of $7.55 billion grew only 0.48% year over year versus $7.51 billion in Q2 2025, and the multi-quarter trend is deteriorating, with revenue falling from $7.91 billion in Q4 2024 to $6.67 billion in Q3 2025 before a modest sequential rebound to $7.55 billion. The parts and other segment at $7.15 billion and financial services at $550 million provide a stabilizing aftermarket and financing cushion, but the core truck business (roughly 74% of sales) is clearly in a cyclical trough, and the near-flat top line implies the investment case now hinges on a volume recovery rather than organic expansion. Profitability remains solid in absolute terms but is compressing: Q2 2026 net income of $752 million on a 16.07% gross margin compares unfavorably to Q2 2025's $723.8 million at a 16.99% gross margin, and the gross margin has slid from 18.60% in Q4 2024 to 13.12% in Q1 2026 before recovering modestly. Operating margin of 10.41% and net margin of 8.35% are respectable for heavy machinery but below the 12.7% operating margin posted in Q4 2024, and the 11.65% EBITDA margin in Q2 2026 versus 15.17% a year earlier confirms meaningful operating leverage working in reverse. The balance sheet is a genuine strength: a current ratio of 3.08, debt-to-equity of 0.81, and $5.57 billion in cash at the end of Q2 2026 provide ample liquidity, while trailing free cash flow of $3.13 billion and ROE of 12.33% demonstrate the business still generates substantial cash. However, quarterly free cash flow has been uneven ($309 million in Q2 2026 versus $1.22 billion in Q3 2025) due to working capital swings and $391.8 million of capex, and the 95.4% payout ratio leaves little room for dividend growth without earnings recovery, though the 3.94% dividend yield offers meaningful income support for patient holders.
Quarterly Revenue
$7.5B
2026-06
Revenue YoY Growth
+0.5%
YoY Comparison
Gross Margin
16.1%
Latest Quarter
Free Cash Flow
$3.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PCAR Overvalued?
Because Paccar is solidly profitable (Q2 2026 net income of $752 million), the PE ratio is the appropriate primary metric, and the trailing PE of 24.23x versus a forward PE of 14.94x implies the market expects earnings to grow roughly 62% — a gap that is unusually wide and suggests either the trailing figure is depressed by the cyclical trough or the forward consensus of $9.29 EPS is optimistic. The forward multiple of 14.94x is far more reasonable for an industrial cyclical and, if achieved, would represent meaningful multiple compression from current levels, making the stock's valuation highly sensitive to whether the earnings recovery materializes. Against the sector, the picture is mixed: the PS ratio of 2.03x and EV/Sales of 2.30x look modest, but the EV/EBITDA of 15.95x and P/B of 2.99x sit at a premium to typical machinery peers, and the 16.23% gross margin and 10.41% operating margin are below what premium industrials typically command, suggesting the market is paying up for franchise quality and the parts/finance annuity rather than current profitability. Historically, Paccar's PE has ranged from roughly 9x in 2023 to 25.8x in Q4 2025, and the current 24.23x trailing multiple sits near the top of that band even as earnings decline — a combination that flags the market as pricing in an optimistic cyclical recovery. The PEG ratio of -0.56 is not meaningful given negative growth, but the P/B of 2.99x versus historical readings near 2.6-3.1x suggests the stock is not cheap on assets either, leaving limited valuation cushion if the freight cycle disappoints.
PE
24.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.9x
Enterprise Value Multiple
Investment Risk Disclosure
Paccar's financial risks are centered on cyclical margin compression and earnings volatility. Gross margin has fallen from 18.60% in Q4 2024 to 16.07% in Q2 2026, and EBITDA margin has contracted from 15.17% to 11.65% over the same period, demonstrating significant operating leverage working in reverse. Revenue growth of just 0.48% year over year in Q2 2026, with revenue falling from $7.91 billion in Q4 2024 to $6.67 billion in Q3 2025, highlights the cyclical trough in the core truck business (74% of sales). The dividend payout ratio of 95.4% leaves little cushion for dividend growth without an earnings recovery, and quarterly free cash flow has been uneven ($309 million in Q2 2026 versus $1.22 billion in Q3 2025) due to working capital swings and $391.8 million of capex. However, the balance sheet is a strength: current ratio of 3.08, debt-to-equity of 0.81, and $5.57 billion in cash provide ample liquidity to weather the downturn.
Market and competitive risks include valuation compression if the earnings recovery fails to materialize. The trailing PE of 24.23x sits near the top of its historical range (9x to 25.8x) even as earnings decline, leaving limited valuation cushion. The stock's beta of 0.988 is in line with the market, but its -22.68% maximum drawdown reflects stock-specific cyclical pressure rather than elevated systematic risk. Competitive threats include the rise of zero-emission powertrains and potential disruption from new entrants, though Paccar's vertically integrated components and 2,200-dealer network provide a durable moat. Regulatory headwinds, such as stricter emissions standards, could increase R&D costs (already $114.3 million in Q2 2026) and pressure margins. Recent news highlights AI-driven data-center infrastructure spending and urbanization trends lifting industrial equipment demand, but these tailwinds may not directly benefit Paccar's core truck business.
The worst-case scenario would involve a prolonged freight recession, causing revenue to stagnate and margins to compress further, leading to earnings below the consensus $9.29 EPS estimate. In this scenario, the stock could retest its 52-week low of $93.86, representing a -12.2% decline from the current $106.96. If the low target of $107.00 is breached and the stock falls to the 52-week low, investors could lose approximately 12% from current levels. A more severe downside scenario, such as a broader market correction or a breakdown below the 52-week low, could see the stock fall toward the $90 level, implying a -16% loss. The analyst low target of $107.00 essentially prices in continued margin compression and no earnings recovery, while the high target of $162.00 assumes a confirmed freight-cycle upturn and multiple expansion.
FAQ
The key risks for PCAR are: (1) cyclical downturn risk—revenue growth has stalled at 0.48% and gross margins have compressed from 18.60% to 16.07%, with further deterioration possible if the freight recession extends; (2) valuation compression risk—the trailing PE of 24.23x is near historical highs, and if the forward EPS estimate of $9.29 proves too optimistic, the stock could de-rate toward its 52-week low of $93.86; (3) dividend sustainability risk—the payout ratio of 95.4% leaves little room for growth, and a prolonged downturn could pressure the dividend; and (4) competitive and regulatory risks—the shift to zero-emission powertrains and stricter emissions standards could increase R&D costs and erode margins. The most severe risk is a prolonged freight recession, which could push the stock down 12-16% from current levels.
Our 12-month forecast for PCAR includes three scenarios: a bull case (25% probability) with a target range of $133-$162, assuming a freight cycle recovery and achievement of the $9.29 EPS estimate; a base case (50% probability) with a target range of $107-$133, assuming gradual recovery and stable margins; and a bear case (25% probability) with a target range of $93.86-$107, assuming a prolonged downturn and earnings disappointment. The base case is most likely, with the stock trading between the analyst low and average targets as the market awaits clearer signs of an earnings recovery. The key assumption is that revenue growth remains in the low single digits and gross margins stabilize around 16-17%.
PCAR appears fairly valued on a forward basis but overvalued on trailing metrics. The forward PE of 14.94x is reasonable for an industrial cyclical and implies a 62% earnings recovery to $9.29 EPS. However, the trailing PE of 24.23x sits near the top of its historical range (9x-25.8x) even as earnings decline, suggesting the market is pricing in an optimistic recovery. The PS ratio of 2.03x and EV/Sales of 2.30x look modest, but the EV/EBITDA of 15.95x and P/B of 2.99x are at a premium to machinery peers. The market appears to be paying for franchise quality and the parts/finance annuity rather than current profitability, leaving limited valuation cushion if the cycle disappoints.
PCAR is a high-quality industrial franchise with a strong balance sheet and a 3.94% dividend yield, but it is currently in a cyclical downturn with revenue growth of just 0.48% and compressing margins. The analyst consensus target of $133.38 implies 24.7% upside, but the low target of $107.00 suggests limited downside protection. The forward PE of 14.94x is attractive if the earnings recovery materializes, but the trailing PE of 24.23x is near historical highs. For long-term investors with a 2-3 year horizon, the stock may be a good buy on further weakness toward the 52-week low of $93.86, but near-term risks remain. It is less suitable for short-term traders given the -19% three-month decline and negative momentum.
PCAR is more suitable for long-term investment (minimum 2-3 years) given its cyclical nature and the current downturn. The stock's beta of 0.988 is in line with the market, but its -22.68% maximum drawdown and -19% three-month decline reflect significant near-term volatility. The 3.94% dividend yield provides income support for patient holders, but the high payout ratio of 95.4% limits dividend growth until earnings recover. Short-term traders may find opportunities around earnings announcements or cyclical inflection points, but the persistent downtrend and negative momentum make timing difficult. A suggested minimum holding period of 2-3 years allows time for the freight cycle to bottom and the earnings recovery to materialize.